Aditi Shastri, MBBS

Experts discuss treatment options for a 70-year-old woman with low-risk MDS, emphasizing the need for more clinical trial data and real-world evidence.

In this concluding segment, the panel reflects on the evolving landscape of treatment for myeloid malignancies, including high-risk MDS and CML, with a focus on oral HMAs. Dr. Fazal emphasizes the importance of clinical trial participation, noting that although some combination therapies may not show overall superiority, subsets of patients demonstrate meaningful benefit, highlighting the need for ongoing research and novel therapeutic strategies.

This segment focuses on practical strategies for managing high-risk CML, particularly in patients with proliferative and cytopenic symptoms. The discussion begins with balancing symptomatic management, such as fatigue, early satiety, splenomegaly, anemia, and thrombocytopenia, alongside disease-directed therapy.

Clinical Scenario A: 77-year-old male with newly diagnosed LR-MDS

Experts debate the optimal dose escalation strategy for Luspatercept in treating low-risk MDS, emphasizing patient-centric approaches and long-term outcomes.

The panel discusses the case of a 67-year-old female patient diagnosed with high-risk chronic myelomonocytic leukemia (CML-1) who presents with intermediate risk scores and abnormal blood counts, including elevated white blood cells, mild thrombocytopenia, and anemia.

This segment continues the discussion of high-risk MDS management, focusing on how clinicians define failure of HMAs and determine next steps in therapy, particularly in patients with TP53 mutations.

Experts debate the efficacy of luspatercept versus erythropoietin in treating low-risk MDS, emphasizing individualized patient care and emerging therapies.

Experts debate the optimal timing for initiating treatment in low-risk MDS, emphasizing early intervention to enhance patient quality of life.

This case-based discussion illustrates the practical management of a 72-year-old patient with high-risk MDS and TP53 mutation.

This segment explores the critical role of patient support programs, insurance navigation, and balancing the convenience of oral HMAs with ongoing clinical oversight.

Explore the promising long-term outcomes of the IMERG trial, highlighting Emtresat's efficacy and safety for lower-risk MDS patients.

Explore real-world outcomes of hemoglobin treatment in low-risk MDS patients, comparing luspatercept and ESA therapies in a recent study.

Explore the practical challenges of using oral hypomethylating agents, focusing on safety, access, and effective patient management strategies.

Explore the differences between bispecific antibodies and CAR T-cell therapy, highlighting their unique benefits and administration processes.

Explore real-world outcomes of Luspatercept and second-line ESAs in treating low-risk MDS, revealing promising response rates and treatment insights.

Explore real-world outcomes of Luspatercept and second-line ESAs in treating low-risk MDS, revealing promising response rates and treatment insights.

FACE-OFF: Low-Risk MDS ASH 2025

Explore the differences between bispecific antibodies and CAR T-cell therapy, highlighting their unique benefits and administration processes in cancer treatment.

FACE-OFF: Low-Risk MDS ASH 2025

Explore the latest advancements in oral hypomethylating agents for MDS and CMML, emphasizing their efficacy, patient convenience, and treatment strategies.